Introduction:
Interleukin-10, human cytokine synthesis inhibitory factor (CSIF), is group of related proteins made by leukocytes and other body cells. It is an anti-inflammatory cytokine. IL-10 plays a key role in differentiation and function of a newly appreciated type of T cell, the T regulatory cell, which prominently control immune responses and tolerance. Interleukin-10 has 20 molecules in their pipeline developed by companies and universities.
Interleukin 10 Pipeline Product Analysis includes products such as AM-0010, ANV-103, BT-063, DEKAVIL/F8 IL10, EG-12, LEO-32731, MK-1966, PD-2244, XT-101, XT-150, Gene Therapy to Activate Interleukin 10 for Atherosclerosis, Gene Therapy to Activate Interleukin-10 for ALS, XT-150, Gene Therapy to Activate Interleukin 10 for Atherosclerosis, Gene Therapy to Activate Interleukin-10 for ALS, Biologic to Activate Glutamic Acid Decarboxylase and IL-10 for Type 1 Diabetes, Biologic to Target Gluten and IL-10 for Celiac Disease, Cell Therapy to Activate IL-10 for Autoimmune Myocarditis and Inflammation, Synthetic Peptides to Inhibit IL-10 and IFN Gamma for Cancer, and Viral Infections and Inflammatory Diseases.
Study objectives of Interleukin 10 Pipeline Product Analysis market:
• To provide a snapshot of the global therapeutic landscape for Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10).
• To review Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• To provide descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
• To determine the key players involved in Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics and enlists all their major and minor projects.
• To assess Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.
Target Audience:
• Companies with Interleukin-10 products
• Government Research Laboratories
• Academic Universities/Institutes
• Research and Development (R&D) Companies
• Market Research and Consulting Service Providers
• Medical Research Laboratories
Key Findings:
• The Interleukin-10 (IL-10) - Pipeline Review involves featured 18 products in pipeline.
• 9 products are in preclinical trials, 4 in phase II, 2 in phase I and 2 studies were discontinued due to tolerance issues.
Key Players:
• The leading market players in the global Interleukin 10 Pipeline Product Analysis include Pfizer Inc., Merck & Co., Inc, Biotest AG, BioMAS Ltd, EnGene Inc., Leo Pharma, Anvil Biosciences, Intrexon Corporation, P2D Biosciences, Xalud Therapeutics INC and others.